Rosetta Genomics Ltd (ROSGQ) Stock Price & News

Rosetta Genomics Ltd. was a molecular diagnostics company with offices in Israel and the United States that uses micro-ribonucleic acid biomarkers to develop diagnostic tests designed to differentiate between various types of cancer. The company expects the first three tests based on its technology to be submitted for regulatory approval in 2008. The diagnostic tests will differentiate between squamous and non-squamous non-small cell lung cancer; differentiate between adenocarcinoma and peritoneal mesothelioma; and seek to identify the origin of tumors in patients representing cancer of unknown primary. Using a single microRNA, the highly sensitive, highly specific test for squamous and non-squamous lung cancer has passed the prevalidation phase and has been submitted for approval to the New York State Department of Health Clinical Laboratory Evaluation Program in April 2008. In April 2008, Nature Biotechnology published a study by Rosetta Genomics’ scientists whose findings demonstrate microRNAs' significant potential to act as effective biomarkers that may be applied in a diagnostic test designed to identify the primary tumor site in patients CUP. Wikipedia

About Rosetta Genomics Ltd

CEO-

Employees86

Founded2000

Headquarters-

SectorBiotechnology

Websiterosettagenomics.com


Revenue
Cost of goods sold
Cost of revenue
Research and development expenses
Total research and development expenses
Selling, general, and admin expenses
Operating expense
Total operating expenses
Operating income
Other non operating income
EBT including unusual items
EBT excluding unusual items
Income tax expense
Effective tax rate
Other operating expenses
Net income
Net profit margin
Earnings per share
Interest and investment income
Interest expense
Net interest expenses
Depreciation and amortization charges
EBITDA
Gain or loss from assets sale

AI content may include mistakes. Learn more

HelpSend feedbackPrivacy Terms Disclaimer

Finance

Ask anything